Antengene Presents AnTenGager-D2 Preclinical Data
Antengene reported preclinical results for its AnTenGager-D2 platform and the KLK2-targeting candidate ATG-109 at the 2026 Society for Immunotherapy of Cancer meeting.
Updated on Nov. 9, 2026 in Biotech
Antengene presented preclinical results of its AnTenGager-D2 Cos-TCE platform in a Rapid Oral Abstract Presentation at the 2026 Society for Immunotherapy of Cancer Annual Meeting. The study, selected as a TOP150 abstract, reported that ATG-109, a KLK2-targeting TCE built on the platform, showed superior preclinical efficacy compared with a clinical benchmark.
Why it matters
The data add to the company's effort to develop next-generation co-stimulatory T-cell engagers for cancer immunotherapy. Antengene said it will further advance these preclinical studies.
The abstract was selected as a TOP150 submission at the 2026 meeting, and ATG-109 outperformed a clinical benchmark in preclinical models. The source does not quantify the efficacy gap or describe the study models, and clinical outcomes remain unknown.
The players
Antengene
Antengene is a Shanghai-based biopharmaceutical company listed on the Stock Exchange of Hong Kong under code 6996.HK, which has obtained 35 investigational new drug approvals in the U.S. and Asia and new drug application approvals in 10 Asia Pacific markets.
The details
AnTenGager-D2 integrates a CD2-based costimulatory design with a novel CD3γε/δε-targeting antibody and steric-hindrance-based CD3 masking. The presentation was designated Poster #896 at the conference.
Timeline
November 8, 2026: Antengene announced the SITC 2026 presentation results.
Big Picture
Bispecific T-cell engagers redirect a patient's T cells toward tumor cells, and Antengene's co-stimulatory design is an attempt to build on that established format. The preclinical comparison against a clinical benchmark places ATG-109 within the competitive race among next-generation TCEs.
For patients with KLK2-expressing cancers, the program remains preclinical, so no treatment access changes yet. The data signal a potential future option, but timelines to clinical use are not stated in the source.
The takeaway
Preclinical advances like AnTenGager-D2 are early steps in a long development pathway, and readers should watch for clinical data before drawing conclusions about patient benefit.
Further reading
Explore more Biotech coverage for context on cancer immunotherapy development.
Source note: This article includes information reported by Daily Journal.
